Morgan Stanley raises target price of Pharmaron Beijing (03759) to HK$31.5, rating "overweight"
In response to the group's 2025 performance, the profit forecast for 2026 to 2030 has been revised upwards by less than 1% to 3% to reflect higher revenue expectations.
Morgan Stanley released a research report stating an updated risk-return profile for Pharmaron Beijing (03759). The target price has been raised from HK$31 to HK$31.5, with a rating of "hold". The bank has adjusted the profit forecast for 2026 to 2030 by less than 1% to 3% in response to the group's 2025 performance in order to reflect expected income increases.
Related Articles
MOMENTUM FIN (01152) issued 555 million shares through the issuance of convertible bonds.
Hanking Gold (03788): MT Bundy gold mine project mining management plan approved and mine operation authorization granted.
DELTON(01989): Partial stock options cancellation completed.
MOMENTUM FIN (01152) issued 555 million shares through the issuance of convertible bonds.
Hanking Gold (03788): MT Bundy gold mine project mining management plan approved and mine operation authorization granted.
DELTON(01989): Partial stock options cancellation completed.
RECOMMEND
